The mortality-to-incidence ratio initially increased in the early 2000s, declined sharply between 2008 and 2011, and remained stable thereafter.

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

Neoadjuvant therapy (NT) in patients with melanoma is associated with promising survival benefits, favorable complete response (CR), and an acceptable safety profile, according to systematic review ...

Nurse-led survivorship care based on PRO triggers reduce unnecessary hospital visits and enhance patient satisfaction.

AT SABCS 2025, researchers presented surgical outcomes for patients who received 6 months of neoadjuvant endocrine therapy for ER-positive, HER2-negative breast cancer.

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

AUD/SUD was significant risk factor for HCC in pre-direct-acting antiviral era, and in the post-direct-acting antiviral era among those with active hepatitis C.

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.

Investigators sought to identify a relationship between cruciferous vegetable intake and breast cancer risk in the Nurses’ Health Study (NHS) and NHSII.

Gut dysbiosis caused by gastric acid suppression has been shown to affect the efficacy of immune checkpoint inhibitor treatment in some cancers, but not in HCC.